Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04065919
Other study ID # IIT#2018-137
Secondary ID
Status Enrolling by invitation
Phase Phase 4
First received
Last updated
Start date October 1, 2019
Est. completion date November 30, 2020

Study information

Verified date February 2020
Source Florida Heart and Lung Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluation of Liposomal Bupivacaine Compared to Usual Care and its Effect on Pain for Cardiac Surgery


Description:

Current standard of care for pain management includes a multimodal approach of peristernal and fifth intercoastal infiltration with 0.25% bupivacaine with epinepherine combined with immediate post operative IV acetaminophen, followed by scheduled oral acetaminophen and supplemental IV and PO narcotics. This practice is beneficial since it controls most of the direct surgical site pain for at least 6 hours, however, after the local anesthetic dissipates, pain is usually managed with the use of opioids combined with scheduled oral acetaminophen.

Opioids are the most commonly used medications to control pain early after surgery because of their high potency. However, their undesirable effects and risk of dependence become limitations.

The Investigators believe Liposomal Bupivacaine would be beneficial in this population due to its quick onset of action and prolonged half-life associated with liposomal formulation ranging from 23.8 to 34.1 hours. The primary endpoint will be a 20% reduction in opioids use.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 300
Est. completion date November 30, 2020
Est. primary completion date October 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age >18 years old

- All open heart surgeries from September 1, 2019 - September 30, 2020

- Able to read, comprehend and sign the informed consent form

Exclusion Criteria:

- Pregnancy

- < 18 years old and prisoners

- Not able to sign informed consent, including patients with an (LAR) legally authorized representative

- Patients with chronic pain requiring scheduled narcotic use

- Stage 4 kidney disease, Child Pugh score suggestive of liver cirrhosis/ disease

- Recent MI within 7 days of scheduled Cardiac surgery

- Known allergy to Liposomal Bupivacaine or derivative of

- Have or is currently involved in a Research Study within 30 days of scheduled surgery

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Liposomal bupivacaine
20mL EXPAREL+40mL bupivacaine 0.25% infiltrated into 5th intercostal space
0.25% Bupivacaine with epinephrine
0.25% Bupivacaine with epinephrine at 1cc/kg total dose infiltrated into 5th intercostal space

Locations

Country Name City State
United States Florida Heart and Lung Institute Gainesville Florida

Sponsors (1)

Lead Sponsor Collaborator
Florida Heart and Lung Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary 20% change in opioids use Record daily narcotic use From post operative day of cardiac surgery through length of hospital admission and through study completion, an average of one year.
Secondary Time to extubation Record in 15 minutes intervals the time when the breathing tube is removed Post operative day of surgery through study completion, an average of 1 year
Secondary Time to ICU Record time in 15 minute intervals the length of time in ICU Post operative day of surgery through study completion, an average of 1 year
Secondary Pain Scores on Post op day 2,3 and 4 Record pain scores using the Wong - Baker" FACES" Pain rating scale and /or CPOT Critical Care Pain Observation Tool. Collecting the Scale ratings of 4-10.*Face #4 Hurts a Little, Face#6 Hurts Even More, Face #8 Hurts a Whole Lot Face#10 Hurts Worst. CPOT- Critical Care Pain Observational Tool Documenting Pain Intensity, Pain Location, Pain Radiation and Pain Description. Post operative day of cardiac surgery through Post operative Day 4
Secondary Total narcotic use on Post op Day 2,3, and 4 Record daily narcotic use both Oral and Intravenous administration Day of cardiac surgery to Post op day 4
Secondary Time to Hospital Discharge Record the number of days(LOS) length of stay in the hospital from post operative surgery to discharge Count the number of days from admission for cardiac surgery to day of hospital discharge through study completion , an average of one year
Secondary Major Adverse Cardiac Effects of Liposomal Bupivacaine Record Major Adverse Cardiac Effects associated with Liposomal Bupivacaine, Arrythmias, Hypotension > 90/50,AV Block and Cardiac Arrest Time of peristernal and fifth intercostal infiltration of liposomal bupivacaine through the expected half life associated with liposomal formulation ranging from 23.8 up to 34.1 hours.
See also
  Status Clinical Trial Phase
Recruiting NCT05968456 - Complexity and Frailty in Cardiothoracic and Vascular Anesthesia (CAfCA). Prospective Multicentric Observational Study
Not yet recruiting NCT05079724 - Acute Kidney Injury After Cardiac Surgery
Terminated NCT01897519 - A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery Phase 2
Completed NCT01847859 - Pocket-size Ultrasound by Nurses in Cardiothoracic Post-operative Patients N/A
Recruiting NCT02863250 - Australian and New Zealand Massive Transfusion Registry
Completed NCT03725098 - Clinical Study Evaluating the Performance of HEMOBLAST Bellows Compared to FLOSEAL Hemostatic Matrix in Cardiothoracic Operations N/A
Terminated NCT00075179 - Natrecor in Pulmonary Hypertension Phase 4
Recruiting NCT02029534 - Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF) Phase 4
Recruiting NCT03639519 - A Trial to Assess the Impact of Ascorbic Acid on Cardiac Surgeries Outcomes and Complications'' Phase 4